Document is current
Any future updates will be listed below
-
Authors
Stein-Thoeringer, Christoph K.
Saini, Neeraj Y.
Zamir, Eli https://orcid.org/0000-0001-8226-5480
Blumenberg, Viktoria https://orcid.org/0000-0003-1379-0876
Schubert, Maria-Luisa
Mor, Uria https://orcid.org/0000-0002-2918-6406
Fante, Matthias A.
Schmidt, Sabine
Hayase, Eiko
Hayase, Tomo
Rohrbach, Roman https://orcid.org/0000-0003-3458-6620
Chang, Chia-Chi
McDaniel, Lauren
Flores, Ivonne
Gaiser, Rogier
Edinger, Matthias
Wolff, Daniel https://orcid.org/0000-0001-7015-3190
Heidenreich, Martin
Strati, Paolo
Nair, Ranjit
Chihara, Dai
Fayad, Luis E.
Ahmed, Sairah
Iyer, Swaminathan P.
Steiner, Raphael E. https://orcid.org/0000-0003-3717-3629
Jain, Preetesh https://orcid.org/0000-0003-2735-168X
Nastoupil, Loretta J. https://orcid.org/0000-0001-6071-8610
Westin, Jason https://orcid.org/0000-0002-1824-2337
Arora, Reetakshi
Wang, Michael L. https://orcid.org/0000-0001-9748-5486
Turner, Joel
Menges, Meghan
Hidalgo-Vargas, Melanie
Reid, Kayla
Dreger, Peter
Schmitt, Anita
Müller-Tidow, Carsten https://orcid.org/0000-0002-7166-5232
Locke, Frederick L. https://orcid.org/0000-0001-9063-6691
Davila, Marco L.
Champlin, Richard E.
Flowers, Christopher R.
Shpall, Elizabeth J.
Poeck, Hendrik
Neelapu, Sattva S. https://orcid.org/0000-0003-1045-4914
Schmitt, Michael https://orcid.org/0000-0002-1579-1509
Subklewe, Marion
Jain, Michael D. https://orcid.org/0000-0002-7789-1257
Jenq, Robert R. https://orcid.org/0000-0002-5434-439X
Elinav, Eran https://orcid.org/0000-0002-5775-2110
-
Funding
Funding for this research was provided by:
Mark Foundation Endeavor Award
- License Information
-
More Information
Article History
Received: 11 October 2022
Accepted: 25 January 2023
First Online: 13 March 2023
Competing interests
: V.B. received research funding from Bristol Myers-Sqibb (BMS)/Celgene, Gilead, Janssen, Novartis, Roche and Takeda, and honoraria from Gilead, Janssen and Novartis. M.-L.S. is a consultant for Novartis, Gilead and Janssen. H.P. is a consultant for Gilead, Abbvie, Pfizer, Novartis, Servier and BMS, and has received research funding from BMS, and honoraria from Novartis, Gilead, Abbvie, BMS, Servier and Janssen-Cilag. M.L.D. reports consultancy/advisory/honoraria for Kite/Gilead, Novartis, Atara, Precision Biosciences, Celyad, Bellicum, GSK, Adaptive Biotech and Anixa Biosciences, and research funding from Kite/Gilead, Novartis and Atara. F.L.L. reports consultancy/advisory fees from Allogene, Amgen, Bluebird Bio, BMS/Celgene, Calibr, Cellular Biomedicine Group, Cowen, EcoR1, Emerging Therapy Solutions, GammaDelta Therapeutics, Gerson Lehrman Groupt, Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen and Umoja, research funding from Kite/Gilead, Allogene, Novartis, BlueBird Bio, BMS, NCI, Leukemia and Lymphoma Society, and education or editorial activity for Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex and Society for Immunotherapy of Cancer. M.D.J. reports consultancy/advisory fees from Kite/Gilead, Novartis, BMS and MyeloidTx, and research funding from Incyte and Kite/Gilead. R.R.J. has served as a consultant or advisory board member for Merck, Microbiome DX, Karius, MaaT Pharma, LisCure, Seres, Kaleido, and Prolacta and has received patent licence fee or stock options from Seres and Kaleido. N.Y.S., C.-C.C., S.S.N., and R.R.J. are inventors on patent applications by the University of Texas MD Anderson Cancer Center, related to the results of the current study entitled "Serum Metabolomics Related to Chimeric Antigen Receptor (CAR) T-Cell Therapy" and "Gut Microbiome as a Predictive Biomarker of Outcomes for Chimeric Antigen Receptor T-Cell Therapy and its Modulation to Enhance Efficacy and Reduce Toxicity". E.E. is a scientific cofounder of DayTwo and BiomX and an advisor to Hello Inside, Igen and Aposense in topics unrelated to this work. The other authors have no competing interests.
